ifosfamide has been researched along with panobinostat in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A | 1 |
2 trial(s) available for ifosfamide and panobinostat
Article | Year |
---|---|
A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxamic Acids; Ifosfamide; Indoles; Male; Middle Aged; Panobinostat; Radiography | 2014 |
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Panobinostat; Survival Rate; Thrombocytopenia; Treatment Outcome; Young Adult | 2018 |